Printer Friendly

PlugBioIn: Plug and play enzymes for an accelerated uptake of Biocatalysis in the Pharmaceutical Industry.

EU contribution: EUR 539 787,5

Objective: At present there is a mismatch between the extensive interest of the pharmaceutical industry to utilize enzyme technology in their production processes and the number of such processes commercially implemented. To overcome this mismatch c-LEcta aims at offering a smart platform of Plug & Play enzymes for the three most relevant enzyme classes (alcohol dehydrogenase, transaminases, and nitrilase). The platform will address the needs of the pharma industry for performing essential biocatalytic reactions suitable for the production of million fold applied chiral active pharmaceutical ingredients (APIs) like Atorvastatin, Rosuvastatin and Duloxetine. The API market is valued at $101.08 billion in 2010. The unique selling proposition of this platform is to comprise

Project completion date : 2017-01-01 12:00:00

Major organization : C-LECTA GMBH

Address : PerlickstraE-e 5

04103 Leipzig

Country :Germany

Email : contact@c-LEcta.com

Url : http://www.c-lecta.com/

Financier : European Union (EU),

Financier address : European Union (EU)

Rue de la Loi 200/Wetstraat 200,

B-1049 Bruxelles/Brussels,

Belgium

Tel: 32-2-2999696, 2993085

Fax: 32-2-2961749

Url: ec.europa.eu/

2015 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Jul 10, 2015
Words:186
Previous Article:LESA: Laser bonding of linear edged super-abrasive blades.
Next Article:IMCESA2020: Innovation Management Capacity Enhancement of SMEs in Saxony-Anhalt for the period 2015-2020 (IMCESA2020).
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters